ResMed (NYSE:RMD) - 주가, 뉴스 및 분석

이 페이지의 번역은 실험적이며 개발 중입니다. 여러분의 환영합니다!

RMD 주식 개요

는 의료 시장을 위한 의료 기기 및 클라우드 기반 소프트웨어 애플리케이션을 개발, 제조, 유통, 판매하는 회사입니다.

RMD 기본 분석
눈송이 점수
가치 평가	5/6
미래 성장	2/6
과거 실적	5/6
재무 상태	6/6
배당금	4/6

보상

공정 가치 추정치보다 낮은 34.3% 에서 거래

수익은 매년 11.49% 증가할 것으로 예상됩니다.

지난 1년간 수익이 13.7% 증가했습니다.

동종업계 및 업계 대비 좋은 가치로 거래

위험 분석

지난 3개월간 상당한 내부자 매도

Community Narratives

Create a narrative

Narratives bring a range of perspectives from our community.

WarrenAI

Based on Analyst Price Targets

Revolutionizing Sleep Health, Wearables, Digital Innovation, And Global Expansion Propel Growth

US$232.83

2.6% overvalued

6.98%

Revenue growth p.a.

21 days ago

ResMed Inc. 경쟁사

Edwards Lifesciences

NYSE:EW

US$40.1b

IDEXX Laboratories

NasdaqGS:IDXX

US$42.1b

DexCom

NasdaqGS:DXCM

US$27.0b

STERIS

NYSE:STE

US$23.6b

가격 내역 및 성능

다음에 대한 모든 사상 최고가, 변동 및 가격 하락 요약 ResMed
과거 주가
현재 주가	US$239.00
52주 최고치	US$255.18
52주 최저치	US$132.24
베타	0.69
11개월 변경	-2.46%
3개월 변경 사항	27.85%
1년 변경 사항	61.63%
33년 변화	-8.85%
5년 변화	80.51%
IPO 이후 변화	35,472.09%

최근 뉴스 및 업데이트

Why ResMed's Rally Is Just Getting Started

Sep 18

ResMed Inc.'s (NYSE:RMD) Earnings Haven't Escaped The Attention Of Investors

Sep 13

Recent updates

An Intrinsic Calculation For ResMed Inc. (NYSE:RMD) Suggests It's 33% Undervalued

Jul 02

ResMed (NYSE:RMD) Seems To Use Debt Quite Sensibly

Apr 30

Earnings Beat: ResMed Inc. Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Models

Apr 30

ResMed Inc.'s (NYSE:RMD) Popularity With Investors Is Clear

Apr 18

With EPS Growth And More, ResMed (NYSE:RMD) Makes An Interesting Case

Mar 22

Capital Investments At ResMed (NYSE:RMD) Point To A Promising Future

Mar 10

An Intrinsic Calculation For ResMed Inc. (NYSE:RMD) Suggests It's 30% Undervalued

Feb 12

Why ResMed Is One Of My Top Picks In 2024

Jan 22

A First Look At ResMed

Jan 09

ResMed Inc.'s (NYSE:RMD) Share Price Could Signal Some Risk

Dec 20

Why You Should Care About ResMed's (NYSE:RMD) Strong Returns On Capital

Dec 06

Shareholders May Find It Hard To Justify Increasing ResMed Inc.'s (NYSE:RMD) CEO Compensation For Now

Nov 10

Are Investors Undervaluing ResMed Inc. (NYSE:RMD) By 41%?

Nov 01

ResMed: Weight-Loss Drug Worries Provide Buying Opportunity

Oct 28

ResMed: Stock Re-Rating To 20x Forward P/E Is A Buy Opportunity

Sep 12

ResMed Has Become A Steal (Rating Upgrade)

Aug 10

ResMed's (NYSE:RMD) Shareholders Will Receive A Bigger Dividend Than Last Year

Aug 07

ResMed (NYSE:RMD) Has Some Way To Go To Become A Multi-Bagger

Jul 30

Here's Why We Think ResMed (NYSE:RMD) Might Deserve Your Attention Today

Jul 16

Compound Your Wealth With ResMed

Jul 04

A Look At The Fair Value Of ResMed Inc. (NYSE:RMD)

Jul 02

We Think ResMed (NYSE:RMD) Can Stay On Top Of Its Debt

May 26

ResMed (NYSE:RMD) Could Be Struggling To Allocate Capital

Apr 24

Here's Why ResMed (NYSE:RMD) Has Caught The Eye Of Investors

Apr 09

A Look At The Intrinsic Value Of ResMed Inc. (NYSE:RMD)

Mar 26

ResMed goes ex dividend tomorrow

Feb 07

ResMed (NYSE:RMD) Seems To Use Debt Quite Sensibly

Feb 06

주주 수익률

	RMD	US Medical Equipment	US 마켓
7D	-2.4%	-0.6%	0.9%
1Y	61.6%	20.8%	32.3%

수익률 대 산업: RMD 지난 1년 동안 9.8 %를 반환한 US Medical Equipment 산업을 초과했습니다.

수익률 대 시장: RMD 지난 1년 동안 25.4 %를 반환한 US 시장을 초과했습니다.

가격 변동성

Is RMD's price volatile compared to industry and market?
RMD volatility
RMD Average Weekly Movement	4.9%
Medical Equipment Industry Average Movement	8.8%
Market Average Movement	6.4%
10% most volatile stocks in US Market	14.8%
10% least volatile stocks in US Market	3.2%

안정적인 주가: RMD 는) 지난 3개월 동안 큰 가격 변동성이 없었습니다.

시간에 따른 변동성: RMD 의 주간 변동성( 6% )은 지난 1년 동안 안정적인 모습을 보였습니다.

회사 소개

설립	직원	CEO	웹사이트
1989	9,980	Mick Farrell	www.resmed.com

는 의료 시장을 위한 의료 기기 및 클라우드 기반 소프트웨어 애플리케이션을 개발, 제조, 유통, 판매하는 회사입니다. 이 회사는 수면 및 호흡기 관리와 서비스형 소프트웨어의 두 가지 부문으로 운영됩니다. 산소포화도, 호흡 노력, 맥박, 비강 흐름, 코골이를 측정하는 휴대용 진단 기기인 ApneaLink Air와 며칠 밤 동안 파생된 말초 동맥 톤, 액티그래피, 산소포화도를 기반으로 AHI를 측정하는 휴대용 클라우드 연결 일회용 진단 기기인 NightOwl 등 다양한 호흡기 질환을 위한 다양한 제품과 솔루션을 제공합니다.

ResMed Inc. 기본 사항 요약

ResMed 의 수익과 매출은 시가총액과 어떻게 비교하나요?
RMD 기본 통계
시가총액	US$35.12b
수익(TTM)	US$1.02b
수익(TTM)	US$4.69b

34.4x

P/E 비율

7.5x

P/S 비율

RMD 주가가 과대평가되어 있나요?

공정 가치 및 가치 분석 보기

수익 및 수익

최신 수익 보고서의 주요 수익성 통계(TTM)
RMD 손익 계산서(TTM)
수익	US$4.69b
수익 비용	US$2.00b
총 이익	US$2.69b
기타 비용	US$1.67b
수익	US$1.02b

최근 보고된 수익

Jun 30, 2024

다음 수익 날짜

n/a

주당 순이익(EPS)	6.95
총 마진	57.38%
순이익 마진	21.79%
부채/자본 비율	14.5%

RMD 의 장기적인 성과는 어땠나요?

과거 실적 및 비교 보기

배당금

0.9%

현재 배당 수익률

28%

지급 비율

RMD 주식 개요

보상

위험 분석

Revolutionizing Sleep Health, Wearables, Digital Innovation, And Global Expansion Propel Growth

ResMed Inc. 경쟁사

NYSE:EW

US$40.1b

NasdaqGS:IDXX

US$42.1b

NasdaqGS:DXCM

US$27.0b

NYSE:STE

US$23.6b

가격 내역 및 성능

최근 뉴스 및 업데이트

Why ResMed's Rally Is Just Getting Started

ResMed Inc.'s (NYSE:RMD) Earnings Haven't Escaped The Attention Of Investors

CEO & Chairman notifies of intention to sell stock

ResMed Elects Christopher DelOrefice to the Board

CEO & Chairman notifies of intention to sell stock

Chief Product Officer recently sold US$10m worth of stock

Recent updates

Why ResMed's Rally Is Just Getting Started

ResMed Inc.'s (NYSE:RMD) Earnings Haven't Escaped The Attention Of Investors

CEO & Chairman notifies of intention to sell stock

ResMed Elects Christopher DelOrefice to the Board

CEO & Chairman notifies of intention to sell stock

Chief Product Officer recently sold US$10m worth of stock

ResMed (NYSE:RMD) Is Increasing Its Dividend To $0.53

Fourth quarter dividend increased to US$0.53

Full year 2024 earnings: Revenues and EPS in line with analyst expectations

ResMed Inc. Declares Quarterly Cash Dividend, Payable on September 19, 2024

Does ResMed (NYSE:RMD) Have A Healthy Balance Sheet?

Returns On Capital Are A Standout For ResMed (NYSE:RMD)

CEO & Chairman notifies of intention to sell stock

ResMed Inc. to Report Q4, 2024 Results on Aug 01, 2024

ResMed: Asymmetrical Value Opportunity With High Prospect Of Re-Rating

An Intrinsic Calculation For ResMed Inc. (NYSE:RMD) Suggests It's 33% Undervalued

CEO & Chairman notifies of intention to sell stock

Now 22% undervalued

CEO & Chairman notifies of intention to sell stock

Investor sentiment improves as stock rises 19%

ResMed (NYSE:RMD) Seems To Use Debt Quite Sensibly

Earnings Beat: ResMed Inc. Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Models

Third quarter dividend of US$0.48 announced

ResMed Inc. Declares Quarterly Cash Dividend, Payable on June 13, 2024

Third quarter 2024 earnings: EPS and revenues exceed analyst expectations

ResMed Inc.'s (NYSE:RMD) Popularity With Investors Is Clear

ResMed Inc. to Report Q3, 2024 Results on Apr 25, 2024

With EPS Growth And More, ResMed (NYSE:RMD) Makes An Interesting Case

Capital Investments At ResMed (NYSE:RMD) Point To A Promising Future

ResMed Inc. Announces the U.S. Launch of the AirFit F40

Founder recently sold US$5.0m worth of stock

Founder notifies of intention to sell stock

An Intrinsic Calculation For ResMed Inc. (NYSE:RMD) Suggests It's 30% Undervalued

Price target increased by 7.3% to US$203

Upcoming dividend of US$0.48 per share at 1.0% yield

Second quarter dividend of US$0.48 announced

Second quarter 2024 earnings released: EPS: US$1.42 (vs US$1.53 in 2Q 2023)

ResMed Inc. Declares Quarterly Cash Dividend, Payable on March 14, 2024

Why ResMed Is One Of My Top Picks In 2024

A First Look At ResMed

ResMed Inc.'s (NYSE:RMD) Share Price Could Signal Some Risk

ResMed Secures Significant Victory in Patent Fight Against New York University

Why You Should Care About ResMed's (NYSE:RMD) Strong Returns On Capital

Resmed Inc. Announces Board Changes

Shareholders May Find It Hard To Justify Increasing ResMed Inc.'s (NYSE:RMD) CEO Compensation For Now

Are Investors Undervaluing ResMed Inc. (NYSE:RMD) By 41%?

Upcoming dividend of US$0.48 per share at 1.4% yield

ResMed: Weight-Loss Drug Worries Provide Buying Opportunity

First quarter 2024 earnings: Revenues and EPS in line with analyst expectations

Resmed Inc. Announces Declared Quarterly Cash Dividend, Payable on December 14, 2023

Price target decreased by 9.0% to US$195

Price target decreased by 7.7% to US$204

ResMed Inc. to Report Q1, 2024 Results on Oct 26, 2023

Price target decreased by 7.3% to US$214

Price target decreased by 9.3% to US$225

ResMed: Stock Re-Rating To 20x Forward P/E Is A Buy Opportunity

CEO & Chairman notifies of intention to sell stock

Investor sentiment deteriorates as stock falls 19%